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Background
Molecular parameters of key interest for monitoring the
efficacy of anti-malaria interventions are those that
quantify effects on transmission or incidence of infec-
tion and disease.
Vaccine trials provide regular follow-up samples of both
comparator groups. In addition, the clinical episodes are
detected and sampled. Provided the spacing of follow up
surveys is in the range of 2-8 weeks, the force of infections
(FOI) can be determined by genotyping all consecutive
samples of all study participants. The molecular FOI is
defined by new parasite clones appearing per time interval.
Individual clones are identified using highly polymorphic
molecular markers in conjunction with high resolution
typing. molFOI is easily detected despite a background of
ongoing infections.
Simultaneously, blood samples from trial participants
become available for RNA based detection and quantifica-
tion of gametocytes by qRT-PCR. Vaccine effects on
gametocyte prevalence can be detected by targeting game-
tocyte-specific transcripts.
Materials and methods
We have evaluated RNA sampling techniques for malaria
field surveys. Collecting samples directly into RNAprotect
solution gave best results. Gametocytes were detected by
qRT-PCR using marker pfs25.
In our cohort studies asexual parasites were genotyped
using marker msp2 and fragment sizing by capillary elec-
trophoresis [1,2]. In the vaccine trial (Phase 2b vaccine
trial of Combination B conducted in Papua New Guinea
[3]) a PCR-RFLP methodology was used. We have devel-
oped the statistical approaches to determining the actual
number of P. falciparum clones aquired per time per indi-
vidual host, corrected for imperfect detectability [4].
Results
Molecular parameters describing the P. falciparum infec-
tion dynamics were estimated based on high precision
genotyping data from cohort studies or from a clinical
trial with repeated follow up bleeds at intervals between 2
weeks and 2 months. The full time-series of presence and
absence of clones in consecutive samples from one indivi-
dual forms the basis from which molFOI, duration of infec-
tion, and clone detectability were estimated.
molFOI in vaccinated children from the Combination B
vaccine trial was significantly reduced in vaccine recipients
only for parasites carrying a 3D7-type msp2 allele corre-
sponding to 3D7 MSP2 component of Combination B.
Conclusions
We demonstrated proof of concept of this approach in a
vaccine trial of the Combination B malaria vaccine. We
propose to consider the molFOI as an outcome measure-
ment in vaccine trials and to collect and preserve in the
field trial setting in parallel blood samples useful for RNA
extractions for monitoring vaccine effects on transmission
stages.
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